TransMedics Group (TMDX) to Release Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.22 per share and revenue of $109.49 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

TransMedics Group Stock Down 5.3 %

Shares of NASDAQ TMDX opened at $73.00 on Wednesday. The firm has a market cap of $2.45 billion, a PE ratio of 77.66 and a beta of 2.12. The company’s fifty day simple moving average is $66.89 and its 200 day simple moving average is $103.27. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on TMDX shares. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Oppenheimer reissued an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group reduced their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Finally, Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.